Drug – bio-affecting and body treating compositions – Lymphokine
Patent
1985-10-28
1991-05-28
Nucker, Christine
Drug, bio-affecting and body treating compositions
Lymphokine
530351, 514 2, 514 8, C07K 1512
Patent
active
050193856
ABSTRACT:
A novel lymphokine, the monoclonal antibody specific to the lymphokine, and their production and uses are disclosed. The lymphokine is a glycoprotein with a molecular weight of 20,000.+-.2,000 daltons; isoelectric point pI, 6.2.+-.0.3; electrophoretic mobility Rf, 0.29.+-.0.02; cytotoxic on L 929 cell; and substantially not growth-inhibitive on KB cell. The lymphokine significantly inhibits the growth of malignant human tumors in vivo. The monoclonal antibody is of IgM or IgG class, and neutralizes specifically the cytotoxic activity of the lymphokine. Combined use of LK 2 with chemotherapeutic such as alkylating agents, metabolic antagonists, antioncotic antibiotics and plant alkaloids enhances greatly the antioncotic effect of the chemotherapeutics.
REFERENCES:
patent: 4276282 (1981-06-01), Sugimoto et al.
patent: 4285929 (1981-08-01), Sugimoto et al.
patent: 4481137 (1984-11-01), Ohnishi et al.
patent: 4758549 (1988-07-01), Mitsuhashi et al.
Zoon, K. Methods in Enzymology, 78, pp. 457-464, 1981.
Chadha, K. C. Methods in Enzymology, 78, pp. 220-226, 1981.
British Search Report.
Kurimoto Masashi
Mitsuhashi Masakazu
Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo
Nucker Christine
LandOfFree
Novel lymphopine LK 2 and pharmaceutic compositions containing s does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Novel lymphopine LK 2 and pharmaceutic compositions containing s, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Novel lymphopine LK 2 and pharmaceutic compositions containing s will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-35089